19 results on '"Noviello S"'
Search Results
2. LBO-02 - BMS-986036 (pegylated FGF21) in patients with non-alcoholic steatohepatitis: a phase 2 study
3. SAT-158 - Factors Impacting SVR12 for Patients with Advanced Cirrhosis Receiving Daclatasvir and Sofosbuvir with Ribavirin in the Ally-1 Study
4. P0866 : Comparative efficacy and tolerability of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for hepatitis C genotype 3: A matching-adjusted indirect comparison
5. P0829 : On-treatment HCVRNA as a predictor of sustained virologic response in HCV genotype 3 infected patients treated with daclatasvir and sofosbuvir: analysis of phase 3 ALLY-3 study
6. P0782 : All-oral 12-week combination treatment with daclatasvir (DCV) and sofosbuvir (SOF) in treatment-experienced patients infected with HCV genotype (GT) 3: A subanalysis of the ALLY-3 phase 3 study
7. LP01 : Daclatasvir plus sofosbuvir for treatment of HCV genotypes 1-4 in HIV-HCV coinfection: The ALLY-2 study
8. LO8 : Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or posttransplant recurrence: Phase 3 ALLY-1 study
9. P1300 EFFICACY AND SAFETY OF DACLATASVIR IN COMBINATION WITH ASUNAPREVIR (DCV+ASV) IN CIRRHOTIC AND NON-CIRRHOTIC PATIENTS WITH HCV GENOTYPE 1B: RESULTS OF THE HALLMARK DUAL STUDY
10. O166 ALL-ORAL DUAL THERAPY WITH DACLATASVIR AND ASUNAPREVIR IN PATIENTS WITH HCV GENOTYPE 1B INFECTION: PHASE 3 STUDY RESULTS
11. 1418 DACLATASVIR COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN FOR 12 OR 16 WEEKS IN PATIENTS WITH HCV GENOTYPE 2 OR 3 INFECTION: COMMAND GT2/3 STUDY
12. 478 INFECTIONS DURING PEGINTERFERON (PEGIFN)/RIBAVIRIN (RBV) THERAPY ARE ASSOCIATED WITH THE MAGNITUDE OF DECLINE IN THE LYMPHOCYTE COUNT: RESULTS OF THE IDEAL STUDY
13. 127 PHOSPHODIESTERASE POLYMORPHISMS MAY BE ASSOCIATED WITH BASELINE THYROID STIMULATING HORMONE (TSH) AND PEGINTERFERON TREATMENT INDUCED HYPOTHYROIDISM IN PATIENTS WITH CHRONIC HEPATITIS C
14. 2015 GENOME WIDE ANALYSIS OF PATIENTS FROM THE IDEAL STUDY IDENTIFIES A CAUSAL ROLE FOR ITPA GENETIC VARIATION IN RIBAVIRIN-INDUCED HEMOLYTIC ANEMIA
15. 304 METABOLIC SYNDROME (MS) IS A NEGATIVE PREDICTOR OF TREATMENT OUTCOME IN PATIENTS WITH CHRONIC HEPATITIS C: RESULTS FROM THE IDEAL STUDY
16. 126 HEMOGLOBIN DECLINE IS ASSOCIATED WITH SVR AMONG HCV GENOTYPE 1-INFECTED PERSONS TREATED WITH PEGINTERFERON (PEG)/RIBAVIRIN (RBV): ANALYSIS FROM THE IDEAL STUDY
17. 991 FINAL RESULTS OF THE IDEAL (INDIVIDUALIZED DOSING EFFICACY VERSUS FLAT DOSING TO ASSESS OPTIMAL PEGYLATED INTERFERON THERAPY) PHASE IIIB STUDY
18. 800 SUSTAINED VIROLOGIC RESPONSE TO INTERFERON ALFA-2B PLUS RIBAVIRIN PREDICTS LONG-TERM CLEARANCE OF HCV IN PEDIATRIC PATIENTS AT 5 YEAR FOLLOW-UP
19. Pharmacokinetics and prophylactic efficacy of imipenem in abdominal surgery
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.